ILU Stock Chart & Stats
€190.56
€0.74(0.60%)
At close: 4:00 PM EDT
€190.56
€0.74(0.60%)
Day’s Range― - ―
52-Week Range€81.50 - €271.25
Previous CloseN/A
Volume243.00
Average Volume (3M)154.00
Market Cap
€39.11B
Enterprise Value€28.37B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)53.4
Beta0.38
Next Earnings
Feb 11, 2027EPS Estimate
1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume186
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€222.00Price Target Upside16.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)4.78
Revenue Forecast (FY)€4.13B
Bulls Say, Bears Say
Bulls Say
NovaSeq X Installed-base GrowthExpanding NovaSeq X placements increase the installed base that generates recurring consumables demand. The high share of transitioned volumes and expected pull-through into 2027 support revenue visibility, deepen customer workflow integration, and strengthen Illumina’s platform economics over the next several quarters.
Strong Profitability And Cash GenerationIllumina’s recovered profitability and substantial free cash flow provide resources to fund research, product development, customer support, and capital allocation without relying entirely on external financing. Strong cash generation also gives the company greater resilience while sequencing demand develops across clinical and research markets.
Clinical Sequencing MomentumClinical consumables growth indicates expanding adoption in a strategically important market with recurring usage after instruments are installed. Combined with raised company guidance, this momentum suggests improving execution and a more durable growth contribution from clinical workflows than from research demand alone.
Bears Say
Research Consumables WeaknessPersistent weakness in research consumables can constrain utilization of Illumina’s installed instruments and offset clinical growth, because consumables are a recurring revenue stream. Continued customer caution and funding uncertainty could therefore slow consolidated growth and delay a broader recovery in sequencing demand.
Moderate Balance-sheet LeverageDebt is manageable alongside current profitability, but leverage reduces financial flexibility if earnings weaken again. Interest obligations and refinancing needs can compete with investment, buybacks, or strategic initiatives, making future operating volatility more consequential for capital allocation and balance-sheet resilience.
Volatile Earnings HistoryThe sharp swing from losses to recovery shows that Illumina’s earnings power has not yet demonstrated consistent durability through different demand conditions. Recent free-cash-flow contraction adds to that concern, since variable profitability and cash conversion can limit confidence in sustained reinvestment capacity.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €81.50 and its highest was €271.25 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €39.11B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 11, 2027 which is in 104 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 29, 2026. The company reported €1.286 earnings per share for the quarter, beating the consensus estimate of €1.211 by €0.075.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.37.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.286 in its last earnings report, beating expectations of €1.211. Following the earnings report the stock price went down -1.692%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in DE:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€222.00 (16.50% Upside)
€222.00 (16.50% Upside)
Blogger Sentiment
Neutral
DE:ILU Sentiment 57%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €391.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
195.28%
12-Months-Change
Fundamentals
Return on Equity
31.08%
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all DE:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILU Stock 12 Month Forecast
Average Price Target
€222.00
▲(16.50% Upside)